We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RCL:NYSERoyal Caribbean Cruises Ltd. Analysis

Data as of 2026-03-10 - not real-time

$290.55

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Royal Caribbean is trading well above its 20‑day and 50‑day moving averages, signaling a bullish price trajectory, while the 14‑day RSI sits in the low‑40s, indicating room for upside without immediate overbought pressure. Technical momentum remains mixed as the MACD shows a bearish divergence, yet the overall trend is classified as bullish and volume is increasing, supporting the price advance. Fundamentally, the company posted a near‑50% jump in full‑year net income and double‑digit revenue growth, with operating margins comfortably above 20% and a forward PE under 15, suggesting earnings momentum. The DCF‑derived fair value exceeds the current market price by roughly a quarter, delivering a compelling upside potential, while the dividend yield of about 1.5% is modest and backed by a payout ratio below 25%. However, the balance sheet is heavily leveraged, with debt‑to‑equity well above 200% and negative free cash flow, which tempers the enthusiasm. High 30‑day volatility and a beta well above the market indicate pronounced price swings, especially in a consumer‑cyclical sector vulnerable to economic headwinds. In sum, the stock offers attractive valuation and earnings growth, but investors must weigh the debt load and volatility against the upside.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price above key moving averages
  • Increasing volume supporting bullish trend
  • Substantial upside to DCF fair value

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong earnings and revenue growth
  • Operating margins above 20%
  • Undervalued relative to intrinsic estimate

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage and negative free cash flow
  • Cyclical exposure to travel demand
  • Sustainable dividend with modest yield

Key Metrics & Analysis

Financial Health

Revenue Growth13.30%
Profit Margin23.80%
P/E Ratio18.6
ROE47.73%
ROA7.81%
Debt/Equity215.09
P/B Ratio7.8
Op. Cash Flow$6.5B
Free Cash Flow$-197624992

Technical Analysis

TrendBullish
RSI42.8
Support$256.31
Resistance$356.39
MA 20$312.63
MA 50$304.20
MA 200$302.42
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89

Valuation

Fair Value$323.40
Target Price$363.50
Upside/Downside25.11%
GradeUndervalued
TypeBlend
Dividend Yield1.53%

Risk Assessment

Beta1.52
Volatility69.04%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.